Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion type Assertion NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_head.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion description "[c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_provenance.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion evidence source_evidence_literature NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_provenance.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion SIO_000772 22198430 NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_provenance.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion wasDerivedFrom befree-20150227 NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_provenance.
- NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_assertion wasGeneratedBy ECO_0000203 NP802727.RAVZp966GTw2lR7lwfud4l0cxvy5sbY_GIL9m-XRxviw0130_provenance.